In a bid to advance research and commercialise regenerative medicine and gene therapy in India, the Association of Biotechnology Led Enterprise (ABLE) -- a consortium of biotechnology companies -- on Friday signed a Memorandum of Understanding (MoU) with a Japan-based trade association.
The collaboration between ABLE and Forum for Innovative Regenerative Medicine (FIRM) will focus on advancing the individual and common missions by sharing information including technology, policy and laws partnerships and opportunities such as co-sponsoring meetings and other cooperation based on common concern.
It will also help advance and promote commercialisation of life saving products in regenerative medicine within India, Japan and other countries.
"We are proud to be a partner in this revolutionary research and industry collaborations. The partnership is a step forward to enhance the learning and training on cell and gene treatment leading to enhancement of the cell and gene therapies which help to address major unmet medical needs in India," P. Manohar, Head (Committee for regenerative medicine group) at ABLE, said in a statement on Friday.
"Our association with ABLE is an opportunity to work towards the advancement of the field (of regenerative medicine and cell and gene therapies) and tap on the potential to transform human healthcare. Through the partnership, we can share learnings and insights to contribute towards curing major human illness," added Yuzo Toda, Chairman at FIRM.